<DOC>
	<DOCNO>NCT02128945</DOCNO>
	<brief_summary>The application positron emission tomography lymphoproliferative disease today provide diagnostic therapeutic information major importance , especially term speed quality response treatment . The radiopharmaceutical use clinical practice exam fluorodeoxyglucose 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose ( [ 18F ] -FDG ) . However , uptake tracer elective lymphoid tissue , lack specificity . In addition , avidity tracer unequal accord histological subtype ( lack sensitivity ) . To try improve result clinical exploration lymphoid malignancy , investigator develop new radiopharmaceutical ( [ 18F ] - fludarabine ) . The idea transform fludarabine radiopharmaceutical base existence fluorine atom molecule pharmacokinetic characteristic drug . The [ 18F ] -Fludarabine new radiopharmaceutical reproducing dosage formulation fludarabine , drug use treatment certain type lymphoproliferative disease , especially tumor cell low proliferation kinetics . This drug use therapy particular pharmacokinetic effect high affinity lymphoid tissue . Preclinical result normal lymphoma xenograft -bearing mouse show specificity restrict lymphoid tissue fixation [ 18F ] -Fludarabine compare [ 18F ] -FDG . Based encouraging result , investigator propose work explore Dosimetry Biodistribution [ 18F ] - Fludarabine human lymphoproliferative disease : 1 ) A first group patient non-Hodgkin 's large cell lymphoma already wealth experience exploration [ 18F ] -FDG , 2 ) second group patient chronic lymphocytic leukemia , result exploration [ 18F ] -FDG consider disappointing , reason , experience clinical development .</brief_summary>
	<brief_title>Dosimetry Biodistribution 18F-Fludarabine Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Adult 18 Signed write informed consent Untreated stage B C chronic lymphocytic leukemia Untreated diffuse large Bcell lymphoma Eligible PETCT The subject must cover social security system Age 18 Patients concurrently include investigational trial Weight 120 kg pregnant woman active infectious disease immune hemolytic anemia patient creatinine clearance &lt; 30 ml/mn corticosteroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>PET</keyword>
	<keyword>Chronic lymphocytic Leukemia ( CLL )</keyword>
	<keyword>Diffuse Large B Cells Lymphoma ( DLBCL )</keyword>
	<keyword>Fludarabine</keyword>
</DOC>